Digestive Health Research
Novo Nordisk Study
Efficacy and Safety Investigation of NNC0194-0499 Co-administered with Semaglutide in Subjects with Non-Alcoholic Steatohepatitis: A Dose-Ranging, Placebo-Controlled Trial
AGE: 18+ years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Nonalcoholic Steatohepatitis (NASH)
CONDITION: Nonalcoholic Steatohepatitis (NASH)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Learn More
For more information, please contact the study coordinator, Katie Northcutt at 216-286-0220 or complete the online form below.
Study Purpose
The purpose of this research study is to see if a combination of 2 medicines (NNC0194-0499 and semaglutide) can reduce liver damage in patients with NASH.
Who Can Participate
Participants 18 years and older with a diagnosis of NASH may be eligible for this study.
- STUDY20220094
- NCT05016882